The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.
 
Daniele Raggi
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Roberto Salvioni
No Relationships to Disclose
 
Siraj Mahamed Ali
Employment - Foundation Medicine; Foundation Medicine
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I)
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Research Funding - Foundation Medicine
 
Jon Chung
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche